Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2020 clinical trials
featured
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

programmed cell death 1 ligand 1
measurable disease
karnofsky performance status
systemic therapy
carcinoma
  • 0 views
  • 23 Nov, 2020
  • 3 locations
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

carcinoma
monoclonal antibodies
tyrosine
ipilimumab
nivolumab
  • 27 views
  • 15 Sep, 2020
  • 1 location
featured
The Axcelsius Study: A Study of ONO-7475 in Patients with Acute Leukemias

What is the Axcelsius study? The Axcelsius study is a clinical research study being conducted to determine the safety and tolerability of the study drug called ONO-7475. ONO-7475 has been tested in AML patients and was confirmed safe and tolerable at a dose to be used in the study. Previous …

refractory acute myeloid leukemia (aml)
venetoclax
induction chemotherapy
acute leukemia
remission
  • 0 views
  • 23 Jul, 2021
  • 3 locations
featured
A Phase 1/2, Open-Label Clinical Study to Evaluate Safety and Efficacy of TP-0184 to Treat Anemia When Administered to Adult Patients with IPSS-R Low or Intermediate Risk of Myelodysplastic Syndromes

This is a Phase 1/2, open-label clinical study to evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS.The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or …

  • 0 views
  • 18 Jun, 2021
  • 3 locations
featured
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).  

organ transplantation
bronchiolitis
bronchiolitis obliterans
lung transplant
  • 11 views
  • 23 Nov, 2020
  • 7 locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

malignant solid tumor
solid tumor
advanced solid tumor
  • 405 views
  • 08 Jul, 2021
  • 73 locations
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the treatment of patients with PIK3CA mutated metastatic colorectal cancer.

measurable disease
metastasis
irinotecan
cetuximab
fluorouracil
  • 2 views
  • 27 Jan, 2021
  • 39 locations
Evaluate the Safety Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on 30 January 2020. In this study, a vaccine developed by IIBR for SARS-CoV-2 virus will …

  • 0 views
  • 03 May, 2021
  • 8 locations
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

  • 0 views
  • 26 Jan, 2021
  • 2 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

  • 0 views
  • 20 Jul, 2021
  • 29 locations